Vonjo improves platelet counts and hemoglobin ranges in sufferers with myelofibrosis.
Enhancements in thrombocytopenia and anemia had been noticed in sufferers with myelofibrosis handled with Vonjo (pacritinib) within the real-world setting, as demonstrated in findings from a retrospective research introduced at the 2024 SOHO Annual Assembly.
In response to the Nationwide Most cancers Institute, thrombocytopenia refers to a situation by which sufferers have a lower-than-normal variety of platelets within the blood, and this can lead to extreme bleeding from wounds and straightforward bruising. Anemia is a situation when sufferers have a low rely of crimson blood cells.
Findings confirmed that sufferers with a platelet rely beneath 100 x 109/L (which is taken into account low) at baseline (74 sufferers) skilled an early improve in platelet rely following therapy initiation that was maintained all through the remark interval. Moreover, an early improve in median hemoglobin (a protein inside crimson blood cells that carries oxygen from lungs to tissues and organs) was reported in all sufferers, and this improve was sustained all through the remark interval. Sufferers with hemoglobin degree of lower than 8 g/dL (a degree that signifies anemia) at first of therapy (35 sufferers) skilled a hemoglobin improve of practically 1 g/dL by day 30.
Notably, sufferers who acquired prior therapy with Jakafi (ruxolitinib; 69 sufferers) skilled a rise in platelet counts and hemoglobin ranges following initiation of Vonjo. At baseline, the median platelet rely and median hemoglobin degree on this inhabitants was 91 x 109/L and eight.7 g/dL, respectively. At day 360, the median platelet rely and median hemoglobin had been 97 x 109/L and 10.4 g/dL, respectively.
“Along with spleen and symptom advantages noticed in earlier medical trials, real-world outcomes exhibit stability or enchancment in thrombocytopenia and/or anemia in sufferers with myelofibrosis handled with [Vonjo],” lead research writer Michael Marrone and colleagues, wrote in a poster presentation of the information. Marrone is an assistant professor within the Faculty of Drugs, Division of Public Well being Sciences, on the Medical College of South Carolina in Charleston.
This retrospective research evaluated the medical and demographic traits, therapy patterns and outcomes of sufferers with myelofibrosis handled with Vonjo in america. In February 2022, the FDA granted accelerated approval to Vonjo for the therapy of adults with intermediate or high-risk main or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet rely beneath 50 x 109/L.
Main outcomes assessed had been adjustments in platelet rely and hemoglobin ranges on the initiation of Vonjo — the index date — and in 30-day intervals post-index. Total survival (the time when a affected person with most cancers remains to be alive; OS) was assessed from index date by the top of the remark interval.
The research included 142 sufferers with myelofibrosis handled with Vonjo at a median follow-up of six months. On this inhabitants, 119 sufferers had full laboratory values obtainable on the index date and not less than one as soon as throughout follow-up.
Notably, at therapy initiation, 28.5% of sufferers had extreme thrombocytopenia with a platelet rely of lower than 50 x 109/L, and 29% had extreme anemia with a hemoglobin degree of lower than 8 g/dL. The median age was 72 years, and the median time from analysis to Vonjo initiation was 13.4 months. The median time from index to the final dose of Vonjo or the top of the remark interval was 5.3 months. In sufferers with a median follow-up of greater than six months (78 sufferers), the median period of Vonjo therapy was 8.5 months.
Extra information confirmed that the 12-month OS chance for sufferers with myelofibrosis handled with Vonjo was 69.4% within the total cohort, which research authors famous was a good final result in contrast with historic JAK inhibitor controls.
Sufferers who acquired Vonjo as a first-line remedy (52 sufferers) had a 12-month OS chance of 77.3%. These with extreme thrombocytopenia handled within the first-line setting (19 sufferers) had a 12-month OS chance of 75.2%.
Amongst sufferers handled with Vonjo within the second-line (59 sufferers), the 12-month OS chance was 72.1%. Sufferers beforehand handled with Jakafi previous to Vonjo had a 12-month OS chance of 65.3%.
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
